FDA Drug Approval System Fails to Protect Public Safety
Submitted by MAGA
Posted 4 hours ago
**Investigation Reveals Deep Flaws in FDA Drug Approval Process, Raising Concerns Over Public Safety**
A recent investigative report has uncovered alarming findings regarding the U.S. Food and Drug Administration’s (FDA) drug approval process.
Between 2013 and 2022, nearly 75% of new drugs approved by the FDA failed to meet the agency’s own scientific standards.
These approvals were found lacking essential scientific criteria, including the use of control groups and blinded studies, raising serious questions about the effectiveness and safety of the medications patients are relying on.
The investigation, conducted by The Lever and the McGraw Center for Business Journalism, reveals that many drugs—and particularly those for cancer and Alzheimer’s—were hastily approved based on unreliable surrogate measures rather than concrete evidence of benefits.
For instance, only 2.4% of cancer medications approved during this period met all four basic scientific criteria.
Alarmingly, 23% of these drugs did not meet any of the four standards.
This troubling reality has left patients and healthcare providers with little assurance of the true efficacy of these medications.
Highlighting an extreme case, the FDA-approved Alzheimer’s drug, Leqembi, has been linked to severe health complications, including brain inflammation and fatalities, yet still saw general approval.
The investigation indicates that the root of these issues stems from systemic shifts in FDA policy that began during the AIDS crisis in the 1980s.
In an effort to expedite access to potentially life-saving treatments, the FDA lowered its standards, allowing drug manufacturers to secure approvals based on limited data and surrogate outcomes like tumor shrinkage.
This focus on speed over scientific integrity has led to a concerning normalization of ineffective drugs on the market.
Medical professionals and researchers are now urging patients to become proactive about their medication regimes, advocating for thorough research into drug approval histories and longer wait times for new drugs to assess their real-world implications.
The new findings call for urgent reform within the FDA to restore rigorous standards and ensure that patient safety remains the agency's paramount concern.
As more information surfaces regarding the FDA's internal practices, it is imperative that both lawmakers and the public demand accountability and transparency from this crucial regulatory authority.
The integrity of our healthcare system relies heavily on the ability of agencies like the FDA to meet their own standards and prioritize scientific evidence over political or commercial pressures.
Americans deserve confidence in the medications prescribed to them, and it is time for a renewed commitment to safeguarding public health through stringent and transparent approval processes.
Sources:
justthenews.com
naturalnews.com
naturalnews.com
A recent investigative report has uncovered alarming findings regarding the U.S. Food and Drug Administration’s (FDA) drug approval process.
Between 2013 and 2022, nearly 75% of new drugs approved by the FDA failed to meet the agency’s own scientific standards.
These approvals were found lacking essential scientific criteria, including the use of control groups and blinded studies, raising serious questions about the effectiveness and safety of the medications patients are relying on.
The investigation, conducted by The Lever and the McGraw Center for Business Journalism, reveals that many drugs—and particularly those for cancer and Alzheimer’s—were hastily approved based on unreliable surrogate measures rather than concrete evidence of benefits.
For instance, only 2.4% of cancer medications approved during this period met all four basic scientific criteria.
Alarmingly, 23% of these drugs did not meet any of the four standards.
This troubling reality has left patients and healthcare providers with little assurance of the true efficacy of these medications.
Highlighting an extreme case, the FDA-approved Alzheimer’s drug, Leqembi, has been linked to severe health complications, including brain inflammation and fatalities, yet still saw general approval.
The investigation indicates that the root of these issues stems from systemic shifts in FDA policy that began during the AIDS crisis in the 1980s.
In an effort to expedite access to potentially life-saving treatments, the FDA lowered its standards, allowing drug manufacturers to secure approvals based on limited data and surrogate outcomes like tumor shrinkage.
This focus on speed over scientific integrity has led to a concerning normalization of ineffective drugs on the market.
Medical professionals and researchers are now urging patients to become proactive about their medication regimes, advocating for thorough research into drug approval histories and longer wait times for new drugs to assess their real-world implications.
The new findings call for urgent reform within the FDA to restore rigorous standards and ensure that patient safety remains the agency's paramount concern.
As more information surfaces regarding the FDA's internal practices, it is imperative that both lawmakers and the public demand accountability and transparency from this crucial regulatory authority.
The integrity of our healthcare system relies heavily on the ability of agencies like the FDA to meet their own standards and prioritize scientific evidence over political or commercial pressures.
Americans deserve confidence in the medications prescribed to them, and it is time for a renewed commitment to safeguarding public health through stringent and transparent approval processes.
Sources:
justthenews.com
naturalnews.com
naturalnews.com
Latest News